Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04088890
Recruitment Status : Recruiting
First Posted : September 13, 2019
Last Update Posted : August 24, 2020
Sponsor:
Information provided by (Responsible Party):
Stanford University

Brief Summary:
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).

Condition or disease Intervention/treatment Phase
B-ALL B-cell Non Hodgkin Lymphoma DLBCL Drug: Fludarabine Drug: Cyclophosphamide Drug: CD22 CAR Phase 1

Detailed Description:

Primary Objective:

  • Determine the feasibility of manufacturing CD22 CAR T cells using the Miltenyi CliniMACS Prodigy® system for administration to adults with relapsed/refractory CD22 expressing B-cell ALL or relapsed/refractory aggressive B-cell non hodgkins lymphoma (NHL).
  • Establish the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of CD22 CAR T cells in adults with relapsed/refractory aggressive B-cell NHL.
  • Determine the safety of an established dose of CD22-CAR T cells in adults with relapsed/refractory CD22 expressing B-cell ALL and the safety of the MTD/RP2D of CD22-CAR T cells in adults with relapsed/refractory aggressive B-cell NHL.

Secondary Objective:

- Assess the clinical activity of CD22-CAR T cells in adults with R/R CD22 expressing B-cell ALL and R/R aggressive B-cell NHL, including overall survival (OS) and progressive free survival (PFS).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 95 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies
Actual Study Start Date : September 12, 2019
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : September 2034

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: R/R ALL

Relapsed/refractory ALL

Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:

  • Fludarabine 30 mg/m2 per day IV for days 5, 4, 3
  • Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3

Autologous CD22 CAR T cells will be administered intravenously at Dose1: 3 x 10^5cells/kg (± 20%) 10

Drug: Fludarabine
Fludarabine 30 mg/m2

Drug: Cyclophosphamide
Cyclophosphamide 500 mg/m2

Drug: CD22 CAR
Autologous T cells transduced with lentiviral vector (CD22.BB.Z) Chimeric Antigen Receptor (CD22 CAR)

Experimental: R/R aggressive B-cell NHL

Relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:

  • Fludarabine 30 mg/m2 per day IV for days 5, 4, 3
  • Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3

Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) to determine MTD/RP2D.

Dose1: 1 x 10^6 cells/kg (± 20%) Dose2: 3 x 10^6 cells/kg (± 20%) Dose3: 1 x 10^7 cells/kg (± 20%)

Drug: Fludarabine
Fludarabine 30 mg/m2

Drug: Cyclophosphamide
Cyclophosphamide 500 mg/m2

Drug: CD22 CAR
Autologous T cells transduced with lentiviral vector (CD22.BB.Z) Chimeric Antigen Receptor (CD22 CAR)




Primary Outcome Measures :
  1. Rate of successful manufacture of CD22 CAR T cells [ Time Frame: 7-11 days from start of manufacturing ]
    The percentage of apheresis samples (fresh or frozen) that are successfully processed and expanded to manufacture CD22 CAR T cells will be determined for each dose cohort.

  2. MTD/RP2D of CD22-CAR T cells in subjects with aggressive B-cell NHL [ Time Frame: 28 days after infusion of CD22 CAR T cells ]
    Incidence and severity of dose limiting toxicities (DLTs) following chemotherapy preparative regimen and infusion of CD22 CAR T cells, as recorded and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, at each dose level tested in subjects with aggressive B-cell NHL

  3. Safe dose of CD22-CAR T cells in subjects with ALL [ Time Frame: 28 days after infusion of CD22 CAR T cells ]
    Incidence and severity of dose limiting toxicities (DLTs) following chemotherapy preparative regimen and infusion of CD22 CAR T cells, as recorded and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, at each dose level tested in subjects with ALL


Secondary Outcome Measures :
  1. Clinical activity of CD22-CAR T cells in adults with relapsed/refractory CD22-expressing B-cell ALL at target dose [ Time Frame: 28 months after infusion of CD22-CAR T cells ]
    Clinical activity will be assessed by modified International Working Group response criteria for acute lymphoblastic leukemia. Results will be reported as best response (i.e. complete response (CR), partial response (PR), stable disease )SD), or progressive disease [PR]) at Day 28 for adult subjects with ALL treated at the target dose.

  2. Clinical activity of CD22-CAR T cells in adults with relapsed/refractory aggressive B-cell NHL at MTD/RP2D [ Time Frame: 3 months after infusion of CD22-CAR T cells ]
    Clinical activity will be assessed by Lugano response criteria for lymphoma (see Appendix 13.3.2). Results will be reported as best response (i.e. complete response [CR], partial response [PR], stable disease [SD], or progressive disease [PR]) at Month 3 for adult aggressive B-cell NHL subjects treated at MTD/RP2D.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Disease Status Disease Status of ALL

    • Must have chemotherapy refractory disease defined as progression or stable disease after two lines of therapies, or relapsed disease after achieving CR.
    • Subjects with persistent or relapsed minimal residual disease (MRD) (by flow cytometry, polymerase chain reaction (PCR), Fluorescence in in situ hybridization (FISH), or next generation sequencing) require verification of MRD on two occasions at least 2 weeks apart.
    • Subjects with Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ALL) are eligible if they progressed, had stable disease or relapsed after two lines of therapy, including tyrosine kinase inhibitors (TKIs).
    • Subjects with recurrence of isolated CNS relapse after achieving complete remission (CR) are eligible.

    Disease Status of aggressive B-cell NHL

    • Histologically confirmed aggressive B cell NHL including the following types defined by WHO 2008:

      - DLBCL not otherwise specified; T cell/histiocyte rich large B cell lymphoma; DLBCL associated with chronic inflammation; Epstein Barr virus (EBV)+ DLBCL of the elderly; OR primary mediastinal (thymic) large B cell lymphoma; OR transformation of follicular lymphoma, marginal zone lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma to DLBCL

    • Subjects with DLBCL or subjects with transformed follicular lymphoma (FL), marginal zone lymphoma (MZL), or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have not received chemotherapy prior to transformation:

      - Must have received an anthracycline regimen and an anti CD20 monoclonal antibody (unless documented CD20-negative) and be refractory or relapsed after second line of DLBCL treatment. Subjects with a partial response to second line therapy must be ineligible for autologous transplant.

    • Subjects with transformed FL, MZL, or CLL/SLL who have received anthracycline-containing chemotherapy prior to transformation:

      • Must have progressed, had SD or recurred with transformed disease after initial treatment for DLBCL.
  2. Measureable Disease

    • Subjects with ALL: must have evaluable or measurable disease (MRD positive by flow cytometry, next-generation sequencing (NGS), or PCR is acceptable).
    • Subjects with aggressive B-cell NHL: must have evaluable or measurable disease according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma[38]. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.
  3. CD22 expression

    • Subjects with ALL: CD22 positive expression on malignant cells is required and must be detected by immunohistochemistry or flow cytometry. The choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each subject.

    CD22 expression must be demonstrated subsequent to any anti-CD22 targeted therapy (e.g. Moxetumomab pasudotox or inotuzumab ozogamicin) in subjects with ALL.

    • Subjects with aggressive B-cell NHL: CD22 expression at any level, including undetectable, will be acceptable. Subjects must have archival tissue available for analysis of CD22 expression or must be willing to undergo a biopsy of easily accessible disease.

  4. Prior Bone Marrow-Stem Cell Transplant Subjects who have undergone autologous stem cell transplant (SCT) with disease progression or relapse following SCT are eligible. Subjects who have undergone allogeneic SCT will be eligible if, in addition to meeting other eligibility criteria, they are at least 100 days post transplant, they have no evidence of graft versus host disease (GVHD) and have been without immunosuppressive agents for at least 30 days.
  5. Prior Therapy Wash-out At least 2 weeks or 5 half lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires 5 half lives.

    Subjects with ALL may not have received inotuzumab ozogamicin therapy within the past 3 months.

    Exceptions:

    1. There is no time restriction with regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such;
    2. Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least 2 weeks prior to starting apheresis;
    3. Subjects who are on standard ALL maintenance type chemotherapy (vincristine, 6-mercaptopurine or oral methotrexate) may be enrolled provided that chemotherapy is discontinued at least 1 week or 5 half lives, whichever is shorter, prior to apheresis.
    4. Subjects receiving steroid therapy at physiologic replacement doses only are allowed provided there has been no increase in dose for at least 2 weeks prior to starting apheresis;
    5. For radiation therapy: Radiation therapy must have been completed at least 3 weeks prior to enrollment, with the exception that there is no time restriction if the volume of bone marrow treated is less than 10% and also the subject has measurable/evaluable disease outside the radiation port or the site of radiation has documented progression.
  6. Prior CAR Therapy Subjects who have undergone prior CAR therapy will be eligible if < 5% of circulating levels of CD3+ cells express the previous CAR by flow cytometry; 30 days must have elapsed post CAR infusion prior to apheresis.
  7. Toxicities due to prior therapy must be stable or resolved (except for clinically non significant toxicities such as alopecia or cytopenias
  8. Age greater than or equal to 18 years of age
  9. Eastern cooperative oncology group (ECOG) performance status of 0, 1, or 2; or Karnofsky ≥ 60%
  10. Normal Organ and Marrow Function (supportive care is allowed per institutional standards, i.e. filgrastim, transfusion)

    • Absolute neutrophil count (ANC) ≥ 750/uL*
    • Platelet count ≥ 50,000/uL*
    • Absolute lymphocyte count (ALC) ≥ 150/uL*

    Adequate renal, hepatic, pulmonary and cardiac function defined as:

    • Creatinine ≤ 2 mg/dL OR creatinine clearance (as estimated by Cockcroft Gault Equation) ≥ 60 mL/min
    • Serum alanine or aspartate aminotransferase (ALT/AST) ≤ 10x Upper limit of normal (ULN) (Elevated ALT/AST related to leukemia involvement of the liver will not disqualify a subject).
    • Total bilirubin ≤ 1.5 mg/dL, except in subjects with Gilbert's syndrome.
    • Cardiac ejection fraction ≥ 45%, no evidence of physiologically significant pericardial effusion as determined by an echocardiogram (ECHO), multigated radionuclide angiography (MUGA) or Cardiac MRI [performed within 180 days or after most recent anthracycline based treatment or mediastinal radiation therapy (whichever is most recent)]
    • No clinically significant ECG findings
    • No clinically significant pleural effusion
    • Baseline O2 saturation > 92% on room air * A subject will not be excluded because of pancytopenia ≥ Grade 3 if it is felt by the investigator to be due to underlying leukemia/lymphoma.
  11. CNS Status Subjects with CNS involvement are eligible as long as there are no overt signs or symptoms that in the evaluation of the investigator would mask or interfere with the neurological assessment of toxicity.
  12. Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)
  13. Contraception Subjects of child bearing or child fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) months after receiving the preparative lymphodepletion regimen.
  14. Ability to give informed consent. Must be able to give informed consent. Legal authorized representative (LAR) is permitted if subject is cognitively able to provide verbal assent.

Exclusion Criteria:

  1. Recurrent or refractory ALL limited to isolated testicular disease.
  2. Hyperleukocytosis (≥ 50,000 blasts/μL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy.
  3. History of other malignancy, unless disease free for at least 3 years. At the discretion of the Principal Investigator, subjects in remission for 1-2 years prior to enrollment may be deemed eligible after considering the nature of other malignancy, likelihood of recurrence during one year following CAR therapy, and impact of prior treatment on risk of CD22-CAR T cells. Subjects in remission <1 year are not eligible.

    • Exception: Nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) is eligible.
    • Hormonal therapy in subjects in remission > 1 year will be allowed.
  4. Presence of fungal, bacterial, viral, or other infection that is uncontrolled. Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.
  5. Ongoing infection with :

    • HIV,
    • Hepatitis B (HBsAg positive) or
    • Hepatitis C virus (HCV) (anti HCV positive). A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing.
  6. CNS disorder such as cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement that in the judgment of the investigator may impair the ability to evaluate neurotoxicity.
  7. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.
  8. Any medical condition that in the judgement of the sponsor investigator is likely to interfere with assessment of safety or efficacy of study treatment.
  9. History of severe immediate hypersensitivity reaction to any of the agents used in this study.
  10. Women who are pregnant or breastfeeding.
  11. In the investigators judgment, the subject is unlikely to complete all protocol required study visits or procedures, including follow up visits, or comply with the study requirements for participation.
  12. Primary immunodeficiency or history of autoimmune disease (e.g. Crohns, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04088890


Contacts
Layout table for location contacts
Contact: Juliana Craig 650-736-0912 jkcraig@stanford.edu

Locations
Layout table for location information
United States, California
Stanford Medical Center Recruiting
Stanford, California, United States, 94304
Contact: Juliana Craig    650-736-0912    jkcraig@stanford.edu   
Principal Investigator: Lori Muffly, MD         
Sponsors and Collaborators
Stanford University
Investigators
Layout table for investigator information
Principal Investigator: Lori Muffly, MD Stanford University
Layout table for additonal information
Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT04088890    
Other Study ID Numbers: IRB-50836
CCT5029 ( Other Identifier: OnCore )
IRB-50836 ( Other Identifier: Stanford IRB )
First Posted: September 13, 2019    Key Record Dates
Last Update Posted: August 24, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Stanford University:
CD22
CAR T cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Neoplasms
Lymphoma, Non-Hodgkin
Lymphoma
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Cyclophosphamide
Fludarabine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists